Merck & Co. Company Profile (NYSE:MRK)

About Merck & Co.

Merck & Co. logoMerck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. The Company's animal health products are sold to veterinarians, distributors and animal producers.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: Pharmaceuticals
  • Exchange: NYSE
  • Symbol: MRK
  • CUSIP: 58933Y10
Key Metrics:
  • Previous Close: $62.96
  • 50 Day Moving Average: $62.85
  • 200 Day Moving Average: $57.69
  • 52-Week Range: €47.97 - €64.00
  • Trailing P/E Ratio: 34.54
  • Foreward P/E Ratio: 16.66
  • P/E Growth: 2.68
  • Market Cap: $174.10B
  • Outstanding Shares: 2,765,208,000
  • Beta: 0.63
Profitability:
  • Net Margins: 13.01%
  • Return on Equity: 23.41%
  • Return on Assets: 10.45%
Debt:
  • Debt-to-Equity Ratio: 0.54%
  • Current Ratio: 1.87%
  • Quick Ratio: 1.52%
Additional Links:
Companies Related to Merck & Co.:

Analyst Ratings

Consensus Ratings for Merck & Co. (NYSE:MRK) (?)
Ratings Breakdown: 12 Hold Ratings, 7 Buy Ratings
Consensus Rating:Hold (Score: 2.37)
Consensus Price Target: €63.27 (0.49% upside)

Analysts' Ratings History for Merck & Co. (NYSE:MRK)
Show:
DateFirmActionRatingPrice TargetDetails
9/14/2016ArgusReiterated RatingBuy$65.00View Rating Details
9/13/2016Morgan StanleySet Price TargetHold$60.00View Rating Details
9/12/2016Jefferies GroupReiterated RatingHold$57.00 -> $56.00View Rating Details
9/11/2016Berenberg BankReiterated RatingHold$62.00View Rating Details
9/9/2016Barclays PLCBoost Price TargetOverweight$66.00 -> $72.00View Rating Details
8/11/2016Sanford C. BernsteinReiterated RatingOutperform$66.00 -> $74.00View Rating Details
8/10/2016Citigroup Inc.Reiterated RatingNeutral$65.00View Rating Details
8/8/2016Piper Jaffray Cos.Reiterated RatingNeutral$58.00 -> $62.00View Rating Details
8/8/2016Deutsche Bank AGBoost Price TargetHold$58.00 -> $59.00View Rating Details
8/7/2016Credit Suisse Group AGUpgradeNeutral -> Outperform$62.00 -> $73.00View Rating Details
8/5/2016BMO Capital MarketsUpgradeMarket Perform -> Outperform$62.00 -> $72.00View Rating Details
7/14/2016Leerink SwannReiterated RatingHold$58.00View Rating Details
6/8/2016Goldman Sachs Group Inc.Reiterated RatingNeutral$60.00View Rating Details
5/19/2016JPMorgan Chase & Co.Reiterated RatingOverweightView Rating Details
5/12/2016Bank of America Corp.Reiterated RatingHoldView Rating Details
4/6/2016Societe GeneraleInitiated CoverageBuyView Rating Details
2/5/2016S&P Equity ResearchReiterated RatingHold$56.00View Rating Details
2/3/2016Cowen and CompanyReiterated RatingHoldView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutralView Rating Details
10/2/2014GuggenheimInitiated CoverageNeutral$65.00View Rating Details
(Data available from 9/25/2014 forward)

Earnings

Earnings History for Merck & Co. (NYSE:MRK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/28/2016        
7/29/2016Q216$0.91$0.93$9.79 billion$9.84 billionViewListenView Earnings Details
5/5/2016Q116$0.85$0.89$9.45 billion$9.30 billionViewN/AView Earnings Details
2/3/2016Q415$0.91$0.93$10.32 billion$10.22 billionViewListenView Earnings Details
10/27/2015Q315$0.91$0.96$10.11 billion$10.10 billionViewListenView Earnings Details
7/28/2015Q215$0.80$0.86$9.81 billion$9.80 billionViewListenView Earnings Details
4/28/2015Q115$0.75$0.85$9.04 billion$9.40 billionViewListenView Earnings Details
2/4/2015Q414$0.86$0.87$10.61 billion$10.48 billionViewListenView Earnings Details
10/27/2014Q314$0.88$0.90$10.66 billion$10.56 billionViewListenView Earnings Details
7/29/2014Q214$0.80$0.85$10.60 billion$10.93 billionViewListenView Earnings Details
4/29/2014Q114$0.79$0.88$10.44 billion$10.30 billionViewListenView Earnings Details
2/5/2014Q413$0.88$0.88$11.39 billion$11.30 billionViewListenView Earnings Details
10/28/2013Q313$0.88$0.92$11.19 billion$11.03 billionViewListenView Earnings Details
7/30/2013Q2 2013$0.82$0.84$11.22 billion$11.01 billionViewListenView Earnings Details
5/1/2013Q1 2013$0.79$0.85$11.09 million$10.70 millionViewListenView Earnings Details
2/1/2013Q4 2012$0.81$0.83$11.46 billion$11.70 billionViewListenView Earnings Details
10/26/2012Q312$0.92$0.95$11.60 billion$11.50 billionViewN/AView Earnings Details
7/27/2012$1.02$1.05ViewN/AView Earnings Details
4/27/2012$0.98$0.99ViewN/AView Earnings Details
2/2/2012$0.95$0.97ViewN/AView Earnings Details
10/28/2011$0.91$0.94ViewN/AView Earnings Details
7/29/2011$0.94$0.95ViewN/AView Earnings Details
4/29/2011$0.84$0.92ViewN/AView Earnings Details
2/3/2011$0.83$0.88ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Merck & Co. (NYSE:MRK)
Current Year EPS Consensus Estimate: $3.74 EPS
Next Year EPS Consensus Estimate: $3.78 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$0.82$0.87$0.84
Q2 20163$0.92$0.92$0.92
Q3 20162$0.95$0.98$0.97
Q4 20162$0.92$1.01$0.97
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Merck & Co. (NYSE:MRK)
Annual Dividend:$1.84
Dividend Yield:2.92%
Dividend Growth:2.30% (3 Year Average)
Payout Ratio:101.10% (Based on Trailing 12 Months of Earnings)
49.20% (Based on Current Year Consensus EPS Estimate)
48.68% (Based on Next Year Consensus EPS Estimate)
Track Record:4 Years of Consecutive Dividend Growth

Dividend History for Merck & Co. (NYSE:MRK)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/26/2016quarterly€0.463.14%9/13/20169/15/201610/7/2016
5/24/2016quarterly€0.463.25%6/13/20166/15/20167/8/2016
2/23/2016quarterly€0.463.64%3/11/20163/15/20164/7/2016
11/24/2015quarterly€0.463.43%12/11/201512/15/20151/8/2016
7/22/2015quarterly€0.453.1%9/11/20159/15/201510/7/2015
5/26/2015quarterly€0.453.03%6/11/20156/15/20157/8/2015
2/24/2015quarterly€0.453.05%3/12/20153/16/20154/8/2015
11/25/2014quarterly€0.453.01%12/11/201412/15/20141/8/2015
7/23/2014quarterly€0.443.02%9/11/20149/15/201410/7/2014
5/27/2014quarterly€0.443.12%6/12/20146/16/20147/8/2014
2/25/2014quarterly€0.443.13%3/13/20143/17/20144/7/2014
11/26/2013quarterly€0.443.53%12/12/201312/16/20131/8/2014
7/24/2013quarterly€0.433.57%9/12/20139/16/201310/7/2013
5/28/2013quarterly€0.433.67%6/13/20136/17/20137/8/2013
2/26/2013quarterly€0.434%3/13/20133/15/20134/5/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Merck & Co. (NYSE:MRK)
Insider Ownership Percentage: 0.05%
Institutional Ownership Percentage: 72.92%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/1/2016Adam H SchechterEVPSell39,200€62.61€2,454,312.00View SEC Filing  
8/10/2016Clark GolestaniEVPSell3,000€63.03€189,090.00View SEC Filing  
8/5/2016Kenneth C FrazierChairmanSell392,000€61.81€24,229,520.00View SEC Filing  
7/5/2016Kenneth C FrazierCEOSell60,000€58.00€3,480,000.00View SEC Filing  
7/5/2016Weir Mirian M GraddickInsiderSell45,000€57.99€2,609,550.00View SEC Filing  
7/1/2016Adam H SchechterEVPSell50,000€57.69€2,884,500.00View SEC Filing  
7/1/2016Weir Mirian M GraddickInsiderSell30,000€57.49€1,724,700.00View SEC Filing  
5/20/2016Clark GolestaniEVPSell39,877€54.79€2,184,860.83View SEC Filing  
4/14/2016Kenneth C FrazierCEOSell131,040€56.11€7,352,654.40View SEC Filing  
11/4/2015Wendell P. WeeksDirectorSell5,000€55.53€277,650.00View SEC Filing  
10/29/2015Adele D. AmbroseinsiderSell37,313€55.08€2,055,200.04View SEC Filing  
10/29/2015Kenneth C. FrazierCEOSell18,666€54.69€1,020,843.54View SEC Filing  
10/28/2015Peter C. WendellDirectorSell5,000€54.85€274,250.00View SEC Filing  
5/11/2015Adam H SchechterEVPSell10,634€60.44€642,718.96View SEC Filing  
5/8/2015Julie L GerberdingEVPSell38,368€60.99€2,340,064.32View SEC Filing  
5/4/2015Bruce N KuhlikInsiderSell56,064€60.20€3,375,052.80View SEC Filing  
4/29/2015Bruce N KuhlikInsiderSell156,902€59.82€9,385,877.64View SEC Filing  
4/29/2015Michael J HolstonEVPSell95,624€59.84€5,722,140.16View SEC Filing  
2/18/2015Kenneth C FrazierCEOSell5,164€58.67€302,971.88View SEC Filing  
2/11/2015Willie A DeeseInsiderSell135,864€58.56€7,956,195.84View SEC Filing  
2/9/2015Peter C WendellDirectorSell5,000€58.76€293,800.00View SEC Filing  
1/15/2015Adam H SchechterEVPSell74,200€62.48€4,636,016.00View SEC Filing  
1/9/2015Kenneth C FrazierCEOSell8,840€62.47€552,234.80View SEC Filing  
12/10/2014Kenneth C FrazierCEOSell9,846€60.00€590,760.00View SEC Filing  
12/8/2014Bruce N KuhlikInsiderSell50,000€62.00€3,100,000.00View SEC Filing  
11/26/2014Rochelle B LazarusDirectorSell10,000€59.63€596,300.00View SEC Filing  
11/24/2014Wendell P WeeksDirectorSell5,000€59.13€295,650.00View SEC Filing  
11/10/2014Kenneth C FrazierCEOSell10,000€57.98€579,800.00View SEC Filing  
10/10/2014Kenneth C FrazierCEOSell9,895€59.73€591,028.35View SEC Filing  
9/10/2014Kenneth C FrazierCEOSell9,814€60.48€593,550.72View SEC Filing  
8/25/2014Adam H SchechterEVPSell22,000€59.70€1,313,400.00View SEC Filing  
8/11/2014Kenneth C FrazierCEOSell10,058€57.00€573,306.00View SEC Filing  
8/4/2014Adele D AmbroseInsiderSell28,669€56.64€1,623,812.16View SEC Filing  
7/10/2014Kenneth C FrazierCEOSell9,987€58.03€579,545.61View SEC Filing  
7/7/2014Weir Mirian M GraddickInsiderSell180,047€59.16€10,651,580.52View SEC Filing  
6/27/2014Willie A DeeseInsiderSell72,290€58.26€4,211,615.40View SEC Filing  
6/10/2014Kenneth C FrazierCEOSell9,985€58.06€579,729.10View SEC Filing  
5/14/2014Adam SchechterEVPSell10,527€55.91€588,564.57View SEC Filing  
4/10/2014Kenneth FrazierCEOSell10,047€57.24€575,090.28View SEC Filing  
4/4/2014Bruce KuhlikInsiderSell145,225€56.43€8,195,046.75View SEC Filing  
2/14/2014Clark GolestaniEVPSell5,990€55.47€332,265.30View SEC Filing  
2/13/2014Bridgette HellerVPSell43,870€55.04€2,414,604.80View SEC Filing  
2/11/2014Adam SchechterEVPSell18,000€55.61€1,000,980.00View SEC Filing  
2/11/2014John CananInsiderSell10,000€55.70€557,000.00View SEC Filing  
2/11/2014Kenneth FrazierCEOSell41,520€54.52€2,263,670.40View SEC Filing  
2/10/2014Peter WendellDirectorSell5,000€54.44€272,200.00View SEC Filing  
2/10/2014Willie DeeseInsiderSell50,000€54.68€2,734,000.00View SEC Filing  
8/7/2013Willie DeeseInsiderSell50,638€48.55€2,458,474.90View SEC Filing  
5/15/2013Adele D AmbroseInsiderSell34,208€46.66€1,596,145.28View SEC Filing  
5/13/2013Bridgette P HellerVPSell5,404€46.15€249,394.60View SEC Filing  
8/9/2012Willie A DeeseInsiderSell62,324€44.26€2,758,460.24View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Merck & Co. (NYSE:MRK)
DateHeadline
wsj.com logo[$$] Merck’s Keytruda Finds Fast Entry Into China Via Medical-Tourism Push (NYSE:MRK)
www.wsj.com - September 24 at 10:39 AM
News IconMerck & Co. To Hold Third-Quarter 2016 Sales And Earnings Conference Call On October 25 (NYSE:MRK)
www.biospace.com - September 23 at 5:50 PM
marketrealist.com logoYou’ve Heard about the EpiPen Debacle, but Have You Heard This? (NYSE:MRK)
marketrealist.com - September 23 at 5:50 PM
News IconMerck's Keytruda Finds Fast Entry Into China Via Medical-Tourism Push (NYSE:MRK)
ih.advfn.com - September 23 at 10:53 AM
publicnow.com logoMerck to Hold Third-Quarter 2016 Sales and Earnings Conference Call on October 25 (NYSE:MRK)
www.publicnow.com - September 23 at 10:53 AM
wsj.com logo[$$] Merck's Keytruda Finds Fast Entry Into China Via Medical-Tourism Push (NYSE:MRK)
www.wsj.com - September 23 at 10:53 AM
News IconThe Insider Activity Don't Lie: Merck & Co., Inc. (NYSE:MRK) (NYSE:MRK)
10thousandcouples.com - September 22 at 5:55 PM
mysmartrend.com logoShares of MRK Up 20.7% Since Uptrend Call on Shares (NYSE:MRK)
www.mysmartrend.com - September 22 at 5:55 PM
capitalcube.com logoMerck & Co., Inc. – Value Analysis (NYSE:MRK) : September 22, 2016 (NYSE:MRK)
www.capitalcube.com - September 22 at 5:55 PM
News IconAnalysts' Recommendations Stocks in Focus: Merck & Co., Inc. (NYSE:MRK) & Gap Inc (NYSE:GPS) - Money News (NYSE:MRK)
www.newsismoney.com - September 22 at 11:02 AM
News IconHC Stocks Updates! Merck & Co., Inc. (MRK), Tokai Pharmaceuticals Inc (NASDAQ:TKAI) - share market updates (press release) (NYSE:MRK)
sharemarketupdates.com - September 21 at 5:55 PM
wallstrt24.com logoTraders Alert - GoPro, (NASDAQ:GPRO), Merck & Co., (NYSE:MRK), Atwood Oceanics, (NYSE:ATW) - Wall Street 24 (NYSE:MRK)
wallstrt24.com - September 21 at 5:55 PM
News IconMerck & Company, Inc. (NYSE:MRK) Analytical Analysis - Newburgh Press (NYSE:MRK)
newburghpress.com - September 21 at 10:21 AM
News IconAnalysts' Recommendations Stocks in Focus: Merck & Co., Inc. (NYSE:MRK) & Adobe Systems Incorporated (NASDAQ ... - Money News (NYSE:MRK)
www.newsismoney.com - September 21 at 10:21 AM
capitalcube.com logoMerck & Co., Inc. breached its 50 day moving average in a Bullish Manner : MRK-US : September 21, 2016 (NYSE:MRK)
www.capitalcube.com - September 21 at 10:21 AM
marketrealist.com logoHow Procysbi Fits into Horizon’s Existing Orphan Drug Portfolio (NYSE:MRK)
marketrealist.com - September 21 at 10:21 AM
News IconShares of Merck & Co., Inc. (NYSE:MRK) & Apache Corporation (NYSE:APA) Stocks News Update: Monday - Money News (NYSE:MRK)
www.newsismoney.com - September 20 at 11:25 AM
publicnow.com logoMerck to Host Investor Teleconference to Discuss ESMO 2016 Highlights (NYSE:MRK)
www.publicnow.com - September 20 at 11:25 AM
marketrealist.com logoHow Multiple Research Programs in Lung Cancer Space Are Impacting Bristol-Myers Squibb (NYSE:MRK)
marketrealist.com - September 20 at 11:25 AM
marketrealist.com logoBristol-Myers Squibb’s Role in the Multiple Myeloma Market (NYSE:MRK)
marketrealist.com - September 20 at 11:25 AM
4-traders.com logoMerck : Nippon Life Insurance Co Lowers stake in Merck & Co. (MRK) (NYSE:MRK)
www.4-traders.com - September 19 at 6:14 PM
News IconStocks Taking Toll on Investment Valuation: Merck & Co., Inc. (NYSE:MRK), Puma Biotechnology, Inc. (NYSE:PBYI) - Street Wise Report (press release) (blog) (NYSE:MRK)
streetwisereport.com - September 19 at 10:45 AM
News IconAnalysts Valuations For Two Stocks: Merck & Co., Inc. (NYSE:MRK), Express Scripts Holding Company (NASDAQ:ESRX) - The Voice Registrar (NYSE:MRK)
voiceregistrar.com - September 19 at 10:45 AM
News IconShares of Merck & Co., Inc. (NYSE:MRK) & Xerox Corp (NYSE:XRX) Stocks News Update: Friday - Money News (NYSE:MRK)
www.newsismoney.com - September 19 at 10:45 AM
marketrealist.com logoAnd Then There’s Merck—Another Competitor for Roche in Oncology (NYSE:MRK)
marketrealist.com - September 19 at 10:45 AM
News IconShares of Merck & Co., Inc. (NYSE:MRK) & Target Corporation (NYSE:TGT) Stocks News Update: Thursday - Money News (NYSE:MRK)
www.newsismoney.com - September 18 at 5:51 PM
News IconHC Stocks Summary! Merck & Co., Inc. (MRK), Tokai Pharmaceuticals Inc (NASDAQ:TKAI) - share market updates (press release) (NYSE:MRK)
sharemarketupdates.com - September 16 at 9:45 AM
thecountrycaller.com logoMerck & Co., Inc. (MRK) and Pfizer Inc. (PFE) a Step Ahead in Diabetes Cure - TCC (NYSE:MRK)
www.thecountrycaller.com - September 16 at 9:45 AM
News IconBlog Coverage Teva Expands its Injectables Portfolio and Banks on Merck Cubicin (NYSE:MRK)
news.investornetwork.com - September 16 at 9:45 AM
News IconMerck & Co., Inc.'s (MRK): Sizzling Stock Alert - Hot Stocks Point - Hot Stocks Point (NYSE:MRK)
www.hotstockspoint.com - September 15 at 6:17 PM
News IconShares of Merck & Co., Inc. (NYSE:MRK) & ArcelorMittal SA (ADR ... - Money News (NYSE:MRK)
www.newsismoney.com - September 15 at 6:17 PM
publicnow.com logoMerck Announces 2016 Recipients of € 1 Million Grant for Multiple Sclerosis Innovation (NYSE:MRK)
www.publicnow.com - September 15 at 6:17 PM
marketwatch.com logoMerck's and Pfizer's diabetes treatment meets primary endpoint of late-stage trial (NYSE:MRK)
www.marketwatch.com - September 15 at 9:39 AM
marketwatch.com logoMerck and Pfizer's diabetes treatment meets primary endpoint of late-stage trial (NYSE:MRK)
www.marketwatch.com - September 15 at 9:39 AM
publicnow.com logoMerck and Pfizer Announce Investigational Ertugliflozin Met Primary Endpoint of A1C Reduction When Added to Sitagliptin and Metformin in People with Type 2 Diabetes (NYSE:MRK)
www.publicnow.com - September 15 at 9:39 AM
businesswire.com logoMerck Publishes 2015/2016 Global Corporate Responsibility Report (NYSE:MRK)
www.businesswire.com - September 14 at 6:20 PM
News IconStocks Ringing Investment Alarms: Merck & Co., Inc. (NYSE:MRK), Mallinckrodt Public Limited Company (NYSE:MNK) - Street Wise Report (press release) (blog) (NYSE:MRK)
streetwisereport.com - September 14 at 10:32 AM
News IconNotable Runner - Merck & Co., Inc.'s (MRK) - Hot Stocks Point - Hot Stocks Point (NYSE:MRK)
www.hotstockspoint.com - September 14 at 10:32 AM
forbes.com logoThe New #13 Most Shorted Dow Component: Merck - Forbes (NYSE:MRK)
www.forbes.com - September 13 at 11:04 AM
News IconActive Run Stocks Logging Brokers' Choice: Merck & Co (NYSE:MRK), American Airlines Group (AAL), EnSync (ESNC) - Street Wise Report (press release) (blog) (NYSE:MRK)
streetwisereport.com - September 13 at 11:04 AM
News IconShares of Merck & Co., Inc. (NYSE:MRK) & CVS Health Corp (NYSE:CVS) Stocks News Update: Monday - Money News (NYSE:MRK)
www.newsismoney.com - September 13 at 11:04 AM
nasdaq.com logoOne Put, One Call Option To Know About for Merck & Co. - Nasdaq (NYSE:MRK)
www.nasdaq.com - September 13 at 11:04 AM
News IconAnalysts Valuations For Two Stocks: Merck & Co., Inc. (NYSE:MRK), Northern Trust Corporation (NASDAQ:NTRS) - The Voice Registrar (NYSE:MRK)
voiceregistrar.com - September 13 at 11:04 AM
thecountrycaller.com logoMerck & Co., Inc. (MRK) PT Slashed To $56 Over Constrained Growth - TCC (NYSE:MRK)
www.thecountrycaller.com - September 13 at 11:04 AM
marketnewsvideo.com logoNotable Monday Option Activity: CSTE, MRK, HLF (NYSE:MRK)
www.marketnewsvideo.com - September 12 at 5:59 PM
News IconDeadline Upcoming in $830 Million Settlement in the Merck & Co Inc (NYSE:MRK) Investor Lawsuit (NYSE:MRK)
www.digitaljournal.com - September 12 at 5:59 PM
nasdaq.com logoMRK January 2019 Options Begin Trading (NYSE:MRK)
www.nasdaq.com - September 12 at 5:59 PM
seekingalpha.com logoMerck's (MRK) CEO Ken Frazier Presents at Morgan Stanley Global Healthcare Broker Conference (Transcript) (NYSE:MRK)
seekingalpha.com - September 12 at 5:59 PM
finance.yahoo.com logoNew Biosimilar can Offer an Effective and Lower Cost Treatment Option for Canadians Living with Rheumatoid Arthritis and Ankylosing Spondylitis (NYSE:MRK)
finance.yahoo.com - September 12 at 10:53 AM
fool.com logoBetter Buy: Merck & Co., Inc. vs. Pfizer (NYSE:MRK)
www.fool.com - September 12 at 10:53 AM

Social

Merck & Co. (NYSE:MRK) Chart for Sunday, September, 25, 2016


Last Updated on 9/25/2016 by MarketBeat.com Staff